FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

LL-37

Cathelicidin / Human Cathelicidin / hCAP-18

Immune & Thymic

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.

작용 메커니즘

Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 50-100mcg subcutaneously daily. Topical applications for wound healing at 10-50mcg/ml. Intranasal protocols studied for upper respiratory infections. Cycles of 1-4 weeks.

연구 노트

Clinical Research Status

LL-37 is actively being investigated in clinical trials for chronic wound healing, with a Phase I/II trial (by Promore Pharma, now Lipigon) demonstrating safety and efficacy in venous leg ulcers. Research applications span chronic infections, biofilm-associated conditions, diabetic wound healing, and as a topical antimicrobial agent. No systemic injectable formulation has reached clinical trials due to challenges with peptide stability and potential hemolytic activity at high systemic concentrations. The connection between vitamin D deficiency and susceptibility to infections has driven research into LL-37 as the mechanistic link.

Key Published Findings

LL-37 demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, including MRSA and Pseudomonas aeruginosa, through membrane disruption mechanisms. A landmark 2006 Science paper showed LL-37 disrupts bacterial biofilms at sub-MIC concentrations by interfering with biofilm attachment and stimulating twitching motility. Research in the Journal of Immunology demonstrated LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells through formyl peptide receptor-like 1 (FPRL1) activation. Studies show vitamin D supplementation increases LL-37 expression 3-5 fold in human macrophages, establishing a direct molecular link between vitamin D status and innate immunity.

Safety Profile

Topical application of LL-37 has been well-tolerated in clinical wound healing trials with no serious adverse events reported. At high systemic concentrations, LL-37 can exhibit cytotoxicity to mammalian cells and hemolytic activity, limiting its use as a systemic injectable. Local injection site reactions including redness and transient pain have been reported but resolve within hours. The peptide is rapidly degraded by serum proteases, which provides a natural safety mechanism against systemic accumulation but limits bioavailability.

Drug Interactions & Contraindications

High-dose vitamin D supplementation increases endogenous LL-37 production and may have additive effects when combined with exogenous LL-37 administration. Concurrent use with other membrane-active antimicrobials (daptomycin, polymyxins) could theoretically produce synergistic cytotoxicity requiring dose adjustment. Patients with rosacea or psoriasis may have elevated endogenous LL-37 levels contributing to their pathology, and exogenous administration could exacerbate these conditions. Not recommended for patients with systemic lupus erythematosus as LL-37-DNA complexes may activate plasmacytoid dendritic cells and worsen autoimmune responses.

Comparison to Related Compounds

Unlike conventional antibiotics, LL-37 kills bacteria through physical membrane disruption, making resistance development extremely difficult compared to target-specific drugs. Compared to other antimicrobial peptides (defensins, magainins), LL-37 is unique in its additional immunomodulatory, angiogenic, and wound-healing properties beyond direct microbial killing. Relative to KPV (another immune peptide), LL-37 is primarily antimicrobial and pro-healing while KPV is primarily anti-inflammatory. Its biofilm-disrupting properties distinguish it from virtually all conventional antibiotics, which are ineffective against established biofilms.

Community Observations

Users primarily employ LL-37 topically or via local subcutaneous injection near chronic wounds, infections, or biofilm-associated conditions at doses ranging from 50-200 mcg. Reports suggest benefit for chronic sinusitis, Lyme disease co-infections, and recurrent skin infections where biofilm involvement is suspected. Many users supplement with vitamin D3 (5,000-10,000 IU daily) to simultaneously boost endogenous LL-37 production alongside exogenous administration. The peptide is considered poorly suited for systemic injection due to rapid degradation and is most often used in targeted, localized applications.

반감기

~4-6 hours

재조성

Sterile water or bacteriostatic water

보관

건조한 상태

Store at -20C for long term.

재조성된 상태

Refrigerate 2-8C. Use within 7 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

CathelicidinHuman CathelicidinhCAP-18

자주 묻는 질문

LL-37란 무엇인가요?

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.

LL-37는 어떻게 작용하나요?

Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.

LL-37의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

LL-37의 반감기는 얼마인가요?

~4-6 hours

LL-37의 다른 이름은 무엇인가요?

Cathelicidin, Human Cathelicidin, hCAP-18

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기